Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters








Database
Language
Publication year range
1.
BMC Cardiovasc Disord ; 24(1): 205, 2024 Apr 10.
Article in English | MEDLINE | ID: mdl-38600454

ABSTRACT

BACKGROUND: Tuberculosis (TB) continues to be a major cause of death across sub-Saharan Africa (SSA). In parallel, non-communicable disease and especially cardiovascular disease (CVD) burden has increased substantially in the region. Cardiac manifestations of TB are well-recognised but the extent to which they co-exist with pulmonary TB (PTB) has not been systematically evaluated. The aim of this study is to improve understanding of the burden of cardiac pathology in PTB in those living with and without HIV in a high-burden setting. METHODS: This is a cross-sectional and natural history study to evaluate the burden and natural history of cardiac pathology in participants with PTB in Lusaka, Zambia, a high burden setting for TB and HIV. Participants with PTB, with and without HIV will be consecutively recruited alongside age- and sex-matched TB-uninfected comparators on a 2:1 basis. Participants will undergo baseline assessments to collect clinical, socio-demographic, functional, laboratory and TB disease impact data followed by point-of-care and standard echocardiography. Participants with PTB will undergo further repeat clinical and functional examination at two- and six months follow-up. Those with cardiac pathology at baseline will undergo repeat echocardiography at six months. DISCUSSION: The outcomes of the study are to a) determine the burden of cardiac pathology at TB diagnosis, b) describe its association with patient-defining risk factors and biochemical markers of cardiac injury and stretch and c) describe the natural history of cardiac pathology during the course of TB treatment.


Subject(s)
HIV Infections , Tuberculosis , Humans , Zambia/epidemiology , HIV Infections/diagnosis , HIV Infections/epidemiology , HIV Infections/complications , Prevalence , Cross-Sectional Studies , Tuberculosis/complications , Tuberculosis/epidemiology
2.
Pan Afr Med J ; 35: 32, 2020.
Article in English | MEDLINE | ID: mdl-32499849

ABSTRACT

INTRODUCTION: In 2009 and 2010, more than 6,000 cholera cases were recorded during these outbreaks with more than 80% of cases recorded in Lusaka province. After a five-year break, in 2016 an outbreak occurred in Lusaka, causing more than 1,000 cases of cholera. This study will strengthen the epidemiological information on the changing characteristics of the cholera outbreaks, for treatment, prevention and control of the disease. METHODS: This was a laboratory-based descriptive cross-sectional study conducted at the University Teaching Hospital in Lusaka, Zambia. A total of 83 V. cholerae O1 isolates were characterised by biochemical testing, serotyping, antimicrobial susceptibility testing, and macrorestriction analysis using Pulsed-Field Gel Electrophoresis. RESULTS: Macrorestriction analysis of the isolates demonstrated high genetic diversity among the isolates with 16 different patterns. The largest pattern comprised 9 isolates while the smallest one had 1 isolate. 2009 and 2010 isolates were highly resistant to nalidixic acid and cotrimoxazole, but highly sensitive to azithromycin and ampicillin. Of the fifty-two isolates from the 2016 cholera outbreak, 90% (47) were sensitive to cotrimoxazole, 94% (49) to tetracycline, and 98% (51) to azithromycin, while 98% (51) were resistant to nalidixic acid and 31(60%) to ampicillin. CONCLUSION: macrorestriction analysis demonstrated high genetic diversity among the V. cholerae O1 strains, suggesting that these isolates were probably not from a similar source. This study also revealed the emergence of multidrug resistance among the 2016 V. cholerae outbreak isolates but were susceptible to cotrimoxazole, tetracycline, and azithromycin, which can be used for treatment of the cholera cases.


Subject(s)
Cholera/microbiology , Vibrio cholerae O1/classification , Vibrio cholerae O1/isolation & purification , Ampicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Azithromycin/therapeutic use , Cholera/drug therapy , Cholera/epidemiology , Cross-Sectional Studies , Disease Outbreaks/history , Drug Resistance, Multiple/genetics , Drug Resistance, Multiple, Bacterial/genetics , Electrophoresis, Gel, Pulsed-Field , Genotype , History, 21st Century , Hospitals, Teaching/statistics & numerical data , Humans , Microbial Sensitivity Tests , Serotyping , Vibrio cholerae O1/genetics , Zambia/epidemiology
3.
BMC Infect Dis ; 17(1): 532, 2017 08 01.
Article in English | MEDLINE | ID: mdl-28764655

ABSTRACT

BACKGROUND: Primary amoebic meningoencephalitis (PAM) is a fulminant disease of the brain caused by Naegleria fowleri. Although the disease is rare, the case fatality rate is very high. In this report, we describe the first case of PAM in Zambia. CASE PRESENTATION: The patient presented with sudden onset of seizures and fever on admission. On physical examination he was febrile, comatose and with a stiff neck. Cerebral spinal fluid (CSF) collected on admission did not reveal any organism on microscopy or culture but showed elevated white cell count. A working diagnosis of severe septicemia with acute meningoencephalitis was then made and the patient was started on IV Cephtriaxone (2 g) twice daily. Despite receiving treatment, his condition deteriorated. A second CSF sample collected on day 3 was also negative for bacteria and other organisms. However, a repeat CSF sample collected on day 8 revealed numerous motile organisms that were identified as Naegleria on microscopy and confirmed to be N. fowleri on polymerase chain reaction. The patient died on day 8 of hospital admission after having received one dose of Amphotericin B (50 mg). Features consistent with PAM were detected on autopsy. CONCLUSION: The isolation of N. fowleri in this patient calls for increased awareness among clinical and laboratory staff on suspected PAM cases to promptly diagnose and effectively manage the disease.


Subject(s)
Central Nervous System Protozoal Infections/diagnosis , Naegleria fowleri/isolation & purification , Amphotericin B/therapeutic use , Animals , Anti-Bacterial Agents/therapeutic use , Cefuroxime/therapeutic use , Central Nervous System Protozoal Infections/complications , Central Nervous System Protozoal Infections/drug therapy , Central Nervous System Protozoal Infections/parasitology , Fatal Outcome , Fever/drug therapy , Humans , Male , Naegleria fowleri/genetics , Sepsis/complications , Sepsis/drug therapy , Young Adult , Zambia
SELECTION OF CITATIONS
SEARCH DETAIL